Advanced Adult Hepatocellular Carcinoma Clinical Trial
Official title:
Phase IIA Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma
Verified date | November 2017 |
Source | Immunovative Therapies, Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, single site, Phase IIA clinical trial to investigate the safety and efficacy of an individualized anti-cancer vaccine (CRCL-AlloVax) in advanced HCC patients.
Status | Completed |
Enrollment | 15 |
Est. completion date | March 2019 |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: 1. Males and females who are at least 18 years of age at time of enrollment 2. Histologically confirmed hepatocellular carcinoma with or without positive HBV and/or HCV, not candidate for local regional intervention 3. Minimum of 90 days of sorafenib treatment or ineligible for sorafenib 4. Child-Pugh Stage A-B (score = 5 and = 9) 5. Performance status: ECOG < 2 with no deterioration over the previous 2 weeks 6. Measurable disease (for mRECIST) 7. Lesion amenable for percutaneous tumor harvest and follow up biopsy 8. Adequate bone marrow, liver and renal function as assessed by the following: - Hemoglobin > 10.0 g/dl - Absolute neutrophil count (ANC) > 1,500/mm3 - Platelet count > 75,000/µl - ALT and AST < 2.5 x ULN - Alkaline phosphatase < 4 x ULN - Serum creatinine < 1.5 9. Women of child-bearing potential: negative pregnancy test 10. Patients of child producing potential: usage of contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental product 11. Ability to understand the study, its inherent risks, side effects and potential benefits and ability to give written informed consent to participate Exclusion criteria: 1. Severe ascites, massive or uncontrolled (+3 on Child-Pugh calculator) 2. Severe encephalopathy, uncontrolled (+3 on Child-Pugh calculator) 3. INR > 1.5 4. Participation in another clinical trial evaluating experimental treatments or procedures or receiving medication/treatment for HCC other than sorafenib 5. Any autoimmune disorder 6. Any clinical condition requiring systemic steroids or current immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 1 month of study entry 7. HIV positive or syphilis 8. History of cardiac disease: congestive heart failure > NYHA class 2; cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or Digoxin are permitted) or uncontrolled hypertension 9. Active clinically serious infections (> grade 2 NCI-CTCAE version 4.0) 10. History of organ or tissue allograft 11. Advanced liver cirrhosis 12. Interferon or thalidomide within 1 month prior to signing informed consent 13. Uncontrolled concurrent serious medical or psychiatric illness 14. Clinically apparent central nervous system metastases or carcinomatous meningitis 15. History of blood transfusion reactions 16. Known allergy to murine monoclonal antibodies or bovine products or cow milk |
Country | Name | City | State |
---|---|---|---|
Thailand | National Cancer Institute of Thailand Address: 268/1 Rama Rd. Ratchathewi | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Immunovative Therapies, Ltd. |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Anti-Tumor Response | Correlation of radiographic tumor burden assessment (mRECIST) with actual tumor burden determined by histological examination of biopsy samples | 30 days | |
Other | Tumor-Specific Immunity | Immunological end-points as surrogate markers of response and/or survival | 30 days | |
Primary | To evaluate survival compared to historical controls | Baseline to date of death from any cause | Approximately 12 months | |
Secondary | To assess AFP as surrogate end-point for response and/or survival | Biomarker concentration will be evaluated at different time points | Approximately 6 months | |
Secondary | To assess mRECIST as surrogate end-point for response and/or survival | Objective tumor responses by mRECIST will be compared with OS | Approximately 6 months | |
Secondary | To evaluate safety in advanced HCC (adverse events) | Subjects will be followed by physical exam, blood labs, CT scan and biopsy for any adverse events | Approximately 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01010126 -
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
|
Phase 2 | |
Completed |
NCT01900002 -
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT01899261 -
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
N/A | |
Completed |
NCT02234986 -
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
|
Phase 2 | |
Completed |
NCT02578602 -
MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
|
Phase 1 | |
Completed |
NCT00608361 -
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT02072486 -
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
N/A | |
Completed |
NCT01839604 -
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
|
Phase 1 | |
Completed |
NCT04576572 -
Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma
|
||
Recruiting |
NCT04022746 -
An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer
|
N/A | |
Completed |
NCT01666756 -
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
|
Phase 1 | |
Recruiting |
NCT02418988 -
Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma
|
Phase 2 | |
Terminated |
NCT01405573 -
Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
|
Phase 3 | |
Completed |
NCT01835223 -
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT01777594 -
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT01829035 -
A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC
|
Phase 3 | |
Active, not recruiting |
NCT02042443 -
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT01015833 -
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03211416 -
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01488487 -
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
|
Phase 2 |